Therapeutic Outcomes of Non-Infectious Scleritis Treated with Tumor Necrosis Factor-Alpha Inhibitors.
| Autor: | Brown JE; Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA., Thomas AS; Tennessee Retina, Nashville, Tennessee, USA., Armbrust KR; Department of Ophthalmology, Minneapolis Veterans Affairs Health Care System, Minneapolis, Minnesota, USA.; Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota, USA., Boyd K; Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA., Berkenstock M; Ocular Immunology Division, Johns Hopkins School of Medicine, Wilmer Eye Institute, Baltimore, Maryland, USA., Kopplin LJ; Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Ocular immunology and inflammation [Ocul Immunol Inflamm] 2024 Aug; Vol. 32 (6), pp. 1017-1023. Date of Electronic Publication: 2023 Apr 12. |
| DOI: | 10.1080/09273948.2023.2191712 |
| Abstrakt: | Purpose: We determine the efficacy of tumor necrosis factor-α (TNF) inhibitors in establishing scleritis quiescence. Methods: We conducted a multicenter retrospective chart review of patients with non-infectious scleritis treated with a TNF inhibitor for at least 6 months. The primary endpoint was scleritis quiescence at 6 months. Secondary endpoints included scleritis quiescence at 12 months, TNF inhibitor effects on concurrent doses of systemic corticosteroids and visual acuity outcomes at 6 and 12 months. Results: At 6 months, 82.2% (37/45) of subjects obtained scleritis quiescence with TNF inhibition. At 12 months, 76.2% (32/42) of subjects remained quiescent. Baseline daily corticosteroid use (21.5 ± 21.6 mg) decreased to 5.4 ± 8.3 mg by 6 months ( p < 0.0001) and 2.8 ± 6.1 mg by 12 months ( p < 0.001). There was no significant difference between the baseline and 6-month BCVA ( p = 0.52). Conclusions: TNF inhibitors are an effective scleritis therapy with significant systemic corticosteroid sparing effect. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|